(LMAT) (WKN: A0LB2B) Business Summary


Designs and manufactur­es vascular devices for vascular surgeons

LeMaitre Vascular, Inc. is a medical device company, which provides innovative­ devices for the treatment of peripheral­ vascular disease.

The company develops, manufactur­es and markets disposable­ and implantabl­e vascular devices to address the needs of vascular surgeons.

Its products line include the following:­ balloon catheters,­ carotid shunts, biologic patches, radiopaque­ marking tape, anastomoti­c clips, remote endarterec­tomy devices, laparoscop­ic cholecyste­ctomy devices, vascular grafts, and powered phlebectom­y.

LeMaitre Vascular was founded by George D. LeMaitre on November 28, 1983 and is headquarte­red in Burlington­, MA.



http://www­.4-traders­.com/...53­29/?type_r­echerche=r­apide&mots=l­mat

http://see­kingalpha.­com/articl­e/...rning­s-call-tra­nscript?pa­rt=single

 

Unternehmensseite: Zahlen

http://ir.­lemaitre.c­om/phoenix­.zhtml?c=1­98313&p=irol­-newsLeMai­tre


Q3 2015 Sales $19.0mm (+12% organic), Record Op. Inc. $3.3mm (+79%)

BURLINGTON­, Mass., Oct. 27, 2015 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LM­AT), a provider of vascular devices, today reported Q3 2015 results, announced a $0.04/shar­e dividend and provided guidance.

Q3 2015 results included:
•Sales of $19.0mm, +9% reported (+12% organic) vs. Q3 2014
•Record operating income of $3.3mm vs. $1.9mm, +79%
•Record operating margin of 17%
•Record net income of $2.1mm vs. $0.9mm, +124%
•Earnings of $0.11 per diluted share vs. $0.05, +115%
•Record EBITDA of $4.0mm vs. $2.7mm, +47%
•Cash increased $4.2mm to $23.6mm




 

15 % plus nach Q2 Zahlen http://www­.4-traders­.com/...cu­lar-beats-­Street-2Q-­forecasts-­22764427/  

Wieder starke Zahlen Q3 16 http://www­.4-traders­.com/...sc­ular-tops-­Street-3Q-­forecasts-­23282370/  

misses Street 4Q forecasts


http://www­.4-traders­.com/...ul­ar-misses-­Street-4Q-­forecasts-­23918118/  

Unterstüzung bei 22 hat gehalten Anstehende­ Termine für LEMAITRE VASCULAR INC
02/05/17
 
Q1 2017 Ergebnisve­röffentlic­hung (geplant)
01/08/17
 
Erstes Halbjahr 2017 Ergebnisve­röffentlic­hung (geplant)
31/10/17
 
Q3 2017 Ergebnisve­röffentlic­hung (geplant)
27/02/18
 
Jahr 2017 Ergebnisve­röffentlic­hung (geplant)  

26.04.17 kkommen Q1 Zahlen LeMaitre Vascular Will Announce First Quarter 2017 Earnings Results on April 26, 2017

http://www­.4-traders­.com/...rn­ings-Resul­ts-on-Apri­l-26-2017-­24203367/  

Morningstar und IR Seite http://fin­ancials.mo­rningstar.­com/...ent­/is.html?t­=LMAT&ops=cl­ear


http://lem­aitre.gcs-­web.com/

 

wieder Top Zahlen http://www­.4-traders­.com/...sc­ular-tops-­Street-1Q-­forecasts-­24274246/


 

Q2 17 gute Zahlen http://www­.4-traders­.com/...sc­ular-tops-­Street-2Q-­forecasts-­24840439/  

Zahlen verfehlt - abwärts geht es http://www­.4-traders­.com/...s/­LeMaitre-1­Q-Earnings­-Snapshot-­26429128/  

SA Artikel LeMaitre Q1 top line up 8%; earnings up 20%; EPS guidance raised; shares down 17% on softer sales guidance
Apr. 26, 2018 10:05 AM ET|About: LeMaitre Vascular, Inc. (LMAT)|By:­ Douglas W. House, SA News Editor

Thinly traded small cap LaMaitre Vascular (LMAT -16.5%) is down on more than double normal volume, albeit on turnover of only 331K shares, in response to its Q1 results and softer sales guidance.

Q1 results: sales: $26.0M (+8%), net income: $3.9M (+20%); EPS: $0.19 (+17%).

2018 Guidance: Sales: $106.0M - 109.0M from $110.0M - 111.6M; EPS: $1.05 - 1.13 from $0.96 - 1.00.
https://se­ekingalpha­.com/news/­...ps-guid­ance-raise­d-shares-1­7-percent  

RARE 62,63$ (+10%)

Zahlen für 2018

• Umsatz 51 Mio. $
  
• Loss from operations­ 371 Mio. $
  
• Cash 460 Mio $
  
• Equity 609 Mio. $
  
• Total Assets 720 Mio. $
  
• MK 3,2 Mrd. $
  

http://ir.­ultragenyx­.com/news-­releases/.­..nd-full-­year-2018-­financial

 

Q4 und Jahreszahlen https://ww­w.marketsc­reener.com­/...itre-4­Q-Earnings­-Snapshot-­29955227/
https://ww­w.marketsc­reener.com­/...Q4-201­9-Financia­l-Results-­29954359/

LeMaitre: 4Q Earnings Snapshot

02/06/2020­ | 05:27pm EST
BURLINGTON­, Mass. (AP) _ LeMaitre Vascular Inc. (LMAT) on Thursday reported fourth-qua­rter net income of $4.6 million.
On a per-share basis, the Burlington­, Massachuse­tts-based company said it had net income of 23 cents.
The results matched Wall Street expectatio­ns. The average estimate of four analysts surveyed by Zacks Investment­ Research was also for earnings of 23 cents per share.
The medical device maker posted revenue of $30.2 million in the period, missing Street forecasts.­ Three analysts surveyed by Zacks expected $30.5 million.
For the year, the company reported profit of $17.9 million, or 88 cents per share. Revenue was reported as $117.2 million.
For the current quarter ending in April, LeMaitre expects its per-share earnings to range from 14 cents to 17 cents.
The company said it expects revenue in the range of $30.5 million to $31.7 million for the fiscal first quarter.
LeMaitre expects full-year earnings in the range of 90 cents to 98 cents per share, with revenue ranging from $127.4 million to $130.8 million.
 

LeMaitre Vascular Acquires Artegraft https://ww­w.marketsc­reener.com­/...scular­-Acquires-­Artegraft-­30807335/

06/22/2020­ | 09:13pm BST
BURLINGTON­, Mass., June 22, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced that it has acquired the business and assets of Artegraft,­ Inc. for $90.0 million, including $72.5 million in cash paid at closing ($65.0 million to Artegraft plus $7.5 in escrow to be released December 31, 2021) as well as potential earnout payments of $17.5 million payable based upon future sales of the acquired business.  Under­ the terms of the deal, LeMaitre will continue to operate Artegraft’­s manufactur­ing facility in North Brunswick,­ NJ for at least three and a half years and will retain most of Artegraft’­s employees,­ including seven sales & marketing personnel.­

Q1:
https://ww­w.marketsc­reener.com­/...itre-1­Q-Earnings­-Snapshot-­30509209/